Verily’s Study Watch Rejected By FDA As Parkinson’s Drug-Development Tool
Executive Summary
US regulators say Verily’s Study Watch – meant to be used in Parkinson’s trials – doesn’t collect data needed to assess whether a patient is truly benefitting from a drug.